success survey

Data from the AcceleRET-Lung trial show an imbalanced risk of severe and fatal infection with pralsetinib for patients with RET fusion-positive NSCLC.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Data presented from a pilot study evaluating HERC validated its usability in measuring equitable practices at leading cancer centers.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Data from TROPiCS-04 did not meet the primary end point of overall survival among those with locally advanced or metastatic urothelial cancer.

Phase 1 expansion data may support potential combination development for IDE397 in NSCLC and urothelial cancer harboring MTAP deletions.